Dr. Abou-Alfa on Sequencing Challenges in Metastatic HCC

Video

In Partnership With:

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses sequencing challenges in metastatic hepatocellular carcinoma (HCC).

One of the key struggles in HCC is deciding how to appropriately sequence the agents available, says Abou-Alfa. The question of whether sequencing should be based on physician preference, tolerance, adverse events, or patient preference is still an open one. These decisions could also be based on science, such as clinical efficacy or other biologic components, says Abou-Alfa. Admittedly, the field does not have those answers yet, adds Abou-Alfa.

The advent of combination therapies has brought everything into the first-line therapy setting, says Abou-Alfa. An additional that then arises is, "Should sorafenib (Nexavar) and lenvatinib (Lenvima) remain as the first- and second-line therapy options and all other agents be moved to the third-line setting?" Although Abou-Alfa admits that this approach might not make sense as all the drugs that are currently available are beneficial. It would not make sense to take away certain assets that might provide benefits for patients, concludes Abou-Alfa.

Related Videos
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD